Who Are Your Target Customers and Market Size?
Your primary customers are biotechnology companies specializing in cell and gene therapies, plus pharmaceutical manufacturers producing high-value biologics. The opportunity is substantial: based on our model, you project scaling Cryogenic Shipments from 450 in 2026 to 2,100 by 2030, driving significant revenue growth.
Financial Outlook and Scale
You project strong initial performance, reaching break-even quickly in January 2026, just one month after launch, though this relies heavily on securing initial contracts and managing the high initial capital expenditure (Capex). Total initial Capex is $1.7 million, including $850,000 for specialized cryogenic transport vehicles.
Here's the quick math on your projected Year 1 revenue and contribution margin. Total fixed operating expenses (Opex) are $49,000/month, or $588,000 annually. Year 1 revenue is $2,789,000. Your variable costs (COGS and Variable Opex) start at 16.5% of revenue (6.5% Liquid Nitrogen, 3.5% Pack